Page Title
Clinical Trial Finder
Ask About Participating in This Study
Nutritional-GICompleted with Results
OPTION: Study of AzurRx MS1819 in people with cystic fibrosis (CF) and exocrine pancreatic insufficiency who are 18 years and older, protocol number AzurRX AZ-CF2001The following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
(this will open in your email program)
Nutritional-GICompleted with Results
OPTION: Study of AzurRx MS1819 in people with cystic fibrosis (CF) and exocrine pancreatic insufficiency who are 18 years and older, protocol number AzurRX AZ-CF2001
This study evaluated the safety and effectiveness of the drug MS1819 as a pancreatic enzyme replacement therapy (PERT). MS1819 is a non-porcine (not pig-derived) lipase-only enzyme for people with CF who have exocrine pancreatic insufficiency (EPI).
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
30% or greater
-
Number of Visits:
10
-
Length of Participation:
11 weeks
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More